Recruiting Clinical Trials

Displaying 51 - 60 of 238 result(s)
Study Title Condition Phase Location
A Randomized, Two-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded, Proof-of-concept Study Investigating the Efficacy, Safety and Tolerability of QUC398 in Patients With Symptomatic Knee Osteoarthritis Osteoarthritis, Knee Phase 2
  • Country: 
    United States
  • Country: 
    Australia
An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib ALK Positive Malignancies Phase 4
  • Country: 
    Brazil
  • Country: 
    China
  • Country: 
    France
  • Country: 
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study Metastatic Breast Cancer Phase 4
  • Country: 
    United States
  • Country: 
    Brazil
  • Country: 
    Hong Kong
  • Country: 
Phase I/II Multicenter Study to Assess Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors Neuroblastoma Phase 1, Phase 2
  • Country: 
    Singapore
A Special Drug Use-results Survey to Evaluate the Safety and Efficacy of Subcutaneous Administration of Cosentyx in Pediatric Patients With Psoriasis Vulgaris, Psoriatic Arthritis, or Pustular Psoriasis Psoriasis Vulgaris, Psoriatic Arthritis, Pustular Psoriasis Not Given
  • Country: 
    Japan
Investigator- and Subject-blinded, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy Trial of CFZ533 in Pediatric and Young Adult Subjects With New Onset Type 1 Diabetes (T1DM) Type 1 Diabetes Mellitus Phase 2
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    Germany
  • Country: 
An Open-label, Phase I, Dose Escalation, Expansion Study of MGY825 in Adult Patients With Advanced Non-small Cell Lung Cancer Non-small Cell Lung Cancer Phase 1
  • Country: 
    United States
  • Country: 
    Germany
  • Country: 
    Japan
  • Country: 
A Phase II, Randomized (1:1) Open Label Study to Assess the Efficacy and Safety of Eltrombopag in Combination With Dexamethasone Compared to Dexamethasone, as First-line Treatment in Adult Patients With Newly Diagnosed Immune Thrombocytopenia Immune Thrombocytopenia (ITP) Phase 2
  • Country: 
    Germany
Exploring the Characteristics and Profiles of Relapsing Multiple Sclerosis Patients Initiated on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf Region Relapsing Multiple Sclerosis Not Given
  • Country: 
    United Arab Emirates
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib Relapsing Multiple Sclerosis Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Belgium
  • Country: